PD 147953

Drug Profile

PD 147953

Alternative Names: FR 139317

Latest Information Update: 17 Apr 2002

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Fujisawa
  • Class
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cerebrovascular disorders; Coronary disorders; Diabetic nephropathies; Heart failure; Hypertension; Ischaemic heart disorders; Myocardial infarction; Renal failure

Most Recent Events

  • 21 Jun 2000 Warner-Lambert has merged with Pfizer
  • 08 Jun 1999 A study has been added to the Hypertension pharmacodynamics section
  • 22 Mar 1999 A preclinical study has been added to the Heart Failure pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top